TGFBR3

Summary

TGFBR3 (transforming growth factor beta receptor 3, HGNC:11774) is a protein-coding gene on chromosome 1p22.1, encoding Transforming growth factor beta receptor type 3 (Q03167). Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis.

This locus encodes the transforming growth factor (TGF)-beta type III receptor. The encoded receptor is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Ectodomain shedding produces soluble TGFBR3, which may inhibit TGFB signaling. Decreased expression of this receptor has been observed in various cancers. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene.

Source: NCBI Gene 7049 — RefSeq curated summary.

At a glance

• GWAS associations: 38
• Clinical variants (ClinVar): 144 total
• Phenotypes (HPO): 15
• MANE Select transcript: NM_003243

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11774
Approved symbol	TGFBR3
Name	transforming growth factor beta receptor 3
Location	1p22.1
Locus type	gene with protein product
Status	Approved
Aliases	betaglycan, BGCAN
Ensembl gene	ENSG00000069702
Ensembl biotype	protein_coding
OMIM	600742
Entrez	7049

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 23 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron, 2 nonsense_mediated_decay

ENST00000212355, ENST00000370399, ENST00000417833, ENST00000465892, ENST00000468996, ENST00000470600, ENST00000525962, ENST00000529608, ENST00000532540, ENST00000533089, ENST00000533370, ENST00000868417, ENST00000868418, ENST00000868419, ENST00000868420, ENST00000868421, ENST00000868422, ENST00000868423, ENST00000868424, ENST00000868425, ENST00000868426, ENST00000868427, ENST00000868428, ENST00000868429, ENST00000868430, ENST00000868431, ENST00000944333, ENST00000944334, ENST00000944335

RefSeq mRNA: 3 — MANE Select: NM_003243 NM_001195683, NM_001195684, NM_003243

CCDS: CCDS30770, CCDS55614

Canonical transcript exons

ENST00000212355 — 17 exons

Exon	Start	End
ENSE00001452590	91680343	91683857
ENSE00001608358	91885878	91886151
ENSE00003469984	91719893	91720230
ENSE00003476285	91708663	91708783
ENSE00003485699	91797287	91797471
ENSE00003490625	91727659	91727806
ENSE00003513471	91719312	91719464
ENSE00003515366	91729805	91729973
ENSE00003552633	91695672	91695779
ENSE00003609889	91734776	91734959
ENSE00003659263	91758613	91758750
ENSE00003670052	91712243	91712542
ENSE00003680288	91716568	91716708
ENSE00003680560	91698089	91698130
ENSE00003687589	91721955	91722144
ENSE00003689932	91716236	91716394
ENSE00003895353	91861471	91861644

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 99.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.9496 / max 290.0997, expressed in 1290 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13249	8.2943	938
13250	2.6901	748
13252	0.5064	239
13251	0.4403	211
13247	0.3724	211
13248	0.3163	163
13253	0.3099	143
13254	0.0200	14

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
renal glomerulus	UBERON:0000074	99.32	gold quality
metanephric glomerulus	UBERON:0004736	99.22	gold quality
synovial joint	UBERON:0002217	99.08	gold quality
calcaneal tendon	UBERON:0003701	99.03	gold quality
mammary duct	UBERON:0001765	98.84	gold quality
tibia	UBERON:0000979	98.72	gold quality
adrenal tissue	UBERON:0018303	98.66	gold quality
seminal vesicle	UBERON:0000998	98.56	gold quality
tendon of biceps brachii	UBERON:0008188	98.55	gold quality
nipple	UBERON:0002030	98.47	gold quality
urethra	UBERON:0000057	98.28	gold quality
pericardium	UBERON:0002407	98.22	gold quality
tendon	UBERON:0000043	98.21	gold quality
cauda epididymis	UBERON:0004360	98.17	gold quality
epithelium of mammary gland	UBERON:0003244	98.13	gold quality
skin of hip	UBERON:0001554	98.05	gold quality
mucosa of stomach	UBERON:0001199	97.99	gold quality
caput epididymis	UBERON:0004358	97.94	gold quality
lower lobe of lung	UBERON:0008949	97.66	gold quality
layer of synovial tissue	UBERON:0007616	97.59	gold quality
mammary gland	UBERON:0001911	97.58	gold quality
thoracic mammary gland	UBERON:0005200	97.56	gold quality
corpus epididymis	UBERON:0004359	97.19	gold quality
parotid gland	UBERON:0001831	97.16	gold quality
kidney epithelium	UBERON:0004819	97.08	gold quality
vena cava	UBERON:0004087	97.04	gold quality
saphenous vein	UBERON:0007318	96.90	gold quality
placenta	UBERON:0001987	96.84	gold quality
mucosa of urinary bladder	UBERON:0001259	96.63	gold quality
colonic epithelium	UBERON:0000397	96.55	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 17.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	688.10
E-CURD-7	yes	381.03
E-ENAD-21	yes	325.26
E-MTAB-6911	yes	126.88
E-ENAD-27	yes	118.49
E-CURD-122	yes	40.15
E-CURD-119	yes	31.01
E-GEOD-81608	yes	21.57
E-HCAD-10	yes	20.65
E-MTAB-9543	yes	18.18
E-HCAD-9	yes	16.56
E-MTAB-5061	yes	15.59
E-MTAB-6678	yes	11.43
E-MTAB-9388	yes	10.81
E-GEOD-83139	yes	10.59

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB5, GATA3, GFI1B, MYCN

miRNA regulators (miRDB)

173 targeting TGFBR3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955

Literature-anchored findings (GeneRIF, showing 40)

• endoglin and betaglycan have a critical role in the regulation of TGFbeta signaling in chondrocytes (PMID:12568406)
• Results quantify the relative expression of inhibin alpha, inhibin/activin beta(A), beta(B), beta(C), follistatin, activin receptors and beta-glycan genes in placental tissue of term pre-eclamptic patients. (PMID:12651901)
• analysis of expression and cellular compartmentalization of the activin receptors ActRIIA, ActRIIB and ActRIB, the inhibin co-receptor (betaglycan), and activin signaling proteins Smads 2, 3 and 4, and growth regulatory role during lactation (PMID:12782414)
• findings indicate a physiologically significant, unanticipated role for beta arrestin 2 in regulating TGF-beta signaling through internalization and subsequent decreased signaling of TGF-beta receptors (PMID:12958365)
• We observed loss of type III TGFbeta receptor (TBR3) expression in all renal cell carcinoma samples (PMID:12970754)
• The specific expression and regulation pattern of betaglycan gene may be related to the functional antagonism of inhibins to activin signal transduction in human ovaries (PMID:14557487)
• Betaglycan mRNA and peptide are expressed by the trophoblast, the decidua and the fetal membranes, but the localization of the peptide in vessel walls is dependent on gestational age. (PMID:14585090)
• expression values for TGF 1 and its receptors I, II, and III were twice as high in the group of patients with a diagnosis of high-grade lymphomas as in the group of patients diagnosed with low-grade lymphomas (PMID:14704634)
• The lower inhibin alpha and betaglycan expression in endometrial adenocarcinoma suggests that the inhibin action may be disrupted. (PMID:15745937)
• This study establishes the first mutational report of the TGFBR3 gene in correlation with ovarian failure. Significant diversity of genotype distribution and haplotype analysis suggested susceptibility of the TGFBR3 gene for ovarian failure aetiology. (PMID:16613887)
• analysis of inhibin and transforming growth factor beta-binding sites on betaglycan (PMID:16621788)
• Mutational analysis of betaglycan/TGF-betaRIII in premature ovarian failure. (PMID:17084394)
• TGFBR3 is the TGF-beta component most commonly downregulated among localized human prostate cancer studies. TGFBR3 knockdown led to focus formation and enhanced expression of CD133, a marker found on prostate cancer stem cells. (PMID:17192875)
• glycosylation of Asn(302) of the alpha-subunit of inhibin A and B results in a decrease in bioactivity, and the effect on inhibin A, at least, is explained by its reduced affinity to betaglycan (PMID:17272393)
• in bone fracture patients, 12 proteins were related to bone/cartilage metabolism, including: TGF-beta induced protein IG-H(3), cartilage acidic protein 1, procollagen C proteinase enhancer protein and TGF-beta receptor III. (PMID:17602227)
• type III transforming growth factor beta receptor has a role in preventing motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression (PMID:17999987)
• The aim of this study was to analyse the profile of TGF-beta1 and the expression of its receptor (TbetaR I, TbetaR II and TbetaR III-betaglycan) genes in IPAH and in secondary forms of pulmonary arterial hypertension [Eisenmenger’s syndrome patients]. (PMID:18097622)
• The ability of TbetaRIII to serve as a cell surface receptor and mediate BMP, inhibin, and TGF-beta signaling suggests a broader role for TbetaRIII in orchestrating TGF-beta superfamily signaling. (PMID:18184661)
• TGF-beta1-mediates downregulation of TbetaRIII mRNA expression through effects on the ALK5/Smad2/3 pathway. (PMID:18299279)
• a high affinity interaction between betaglycan and residues Val(108)-Tyr(120) of the inhibin alpha-subunit mediate inhibin A biological activity (PMID:18397882)
• Mesenchymal stem cells from patients with osteoarthritis showed significantly increased total TGF-beta, TGF-beta1 isoform, TBR-II, and TBR-III mRNA expression compared to controls. (PMID:18398939)
• clathrin-independent endocytosis of T beta RIII has a role in regulating both Smad-dependent and Smad-independent TGF-beta signaling (PMID:18845534)
• Report overexpression of TGFBR3 in pancreatic islets of nesidioblastosis patients. (PMID:18931647)
• Stratified linkage analysis followed by association testing identified TGFBR3 (betaglycan) as a potential susceptibility gene for COPD. (PMID:19131638)
• These data suggest that loss of betaglycan contributes to the pathogenesis of ovarian granulosa cell tumors. (PMID:19164448)
• ADAMTS18 and TGFBR3 might underlie BMD determination in the major human ethnic groups. (PMID:19249006)
• an unexpected TGF-beta signaling independent role for TbetaRIII in activating Cdc42, altering the actin cytoskeleton and reducing directional persistence to inhibit random migration of both cancer and normal epithelial cells (PMID:19416857)
• results of this study suggest that TGFbetaRIII is transcriptionally down-regulated in hepatocellular carcinoma; in addition, genetic alterations did not appear to be associated with the reduced expression level of TGFbetaRIII (PMID:19639191)
• Partial plasmin digestion of soluble betaglycan produces two proteolysis-resistant fragments of 45 and 55 kilodaltons (kDa) corresponding, respectively, to betaglucan membrane-distal and -proximal regions. (PMID:19842711)
• A review on the role of TbetaRIII as a suppressor of cancer progression and/or as a metastasis suppressor. (PMID:20153821)
• report demonstrates the aberrantly increased expression of betaglycan mRNA in polycystic ovary syndrome ovaries; mechanism by which betaglycan contributes to the pathologic process of PCOS remains to be clarified (PMID:20178540)
• Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. (PMID:20208565)
• Association of genetic variants in TGFBR3 and asthma in a Korean population. (PMID:20386084)
• Use of sucrose-density ultracentrifugation to isolate membrane-raft fractions demonstrates recruitment of both TGFBbeta receptor (TGFbetaR)II and TGFbetaRI to non-raft membrane fractions by TGFbetaRIII. (PMID:20406198)
• Reduced expression of TGFBR3 was observed in non-small cell lung cancer(NSCLC) cell lines, especially in 95D, suggesting that TGFBR3 might play an important role in development and progression of NSCLC. (PMID:20677641)
• endometrial cancer is associated with disruption of accessory receptor betaglycan expression, what may alter TGFbeta2-induced signaling. (PMID:21261473)
• TGFBR3 is associated with acute lung injury in mice (PMID:21297076)
• Polymorphisms of ATOH7, TGFBR3 and CARD10 influence the size of optic disc area. (PMID:21307088)
• type III transforming growth factor-beta protein expression is decreased in human multiple myeloma specimens. (PMID:21411633)
• Chromosomal translocation t(1;10) is consistent with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. (PMID:21717526)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tgfbr3	ENSDARG00000099979
mus_musculus	Tgfbr3	ENSMUSG00000029287
rattus_norvegicus	Tgfbr3	ENSRNOG00000002093

Paralogs (2): ENG (ENSG00000106991), TGFBR3L (ENSG00000260001)

Protein

Protein identifiers

Transforming growth factor beta receptor type 3 — Q03167 (reviewed: Q03167)

Alternative names: Betaglycan, Transforming growth factor beta receptor III

All UniProt accessions (5): Q03167, A0A0A8KWK3, E9PAW7, E9PKY4, E9PMG7

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis. Initiates BMP, inhibin, and TGF-beta signaling pathways by interacting with different ligands including TGFB1, BMP2, BMP5, BMP7 or GDF5. Alternatively, acts as a cell surface coreceptor for BMP ligands, serving to enhance ligand binding by differentially regulating BMPR1A/ALK3 and BMPR1B/ALK6 receptor trafficking. Promotes epithelial cell adhesion, focal adhesion formation and integrin signaling during epithelial cell spreading on fibronectin. By interacting with the scaffolding protein beta-arrestin2/ARRB2, regulates migration or actin cytoskeleton and promotes the activation of CDC42 as well as the inhibition of NF-kappa-B. In gonadotrope cells, acts as an inhibin A coreceptor and regulates follicle-stimulating hormone (FSH) levels and female fertility. Plays a role in the inhibition of directed and random cell migration in epithelial cells by altering the actin cytoskeletal organization. Participates in epithelial-mesenchymal transformation (EMT) upon binding to BMP2 or TGFB2, by activating the PAR6/SMURF1/RHOA pathway. (Microbial infection) May act as a receptor for human cytomegalovirus in different cell types by interacting with HCMV trimer composed of GO, GH and GL.

Subunit / interactions. Forms homodimers and homooligomers. Interacts with DYNLT4. Interacts with integrin ITGA5:ITGB1; this interaction promotes the internalization and trafficking of ITGA5:ITGB1 into endocytic vesicles. Interacts with TGFB1, BMP2, BMP5, BMP7 or GDF5 and inhibin A via the ligand binding domains. Interacts with ALK3/BMPR1A; this interaction results in the cell surface retention of BMPR1A. Interacts with ALK6/BMPR1B; this interaction enhances BMPR1B-mediated stimulation of the BMP signaling pathway. Interacts with the scaffolding protein beta-arrestin2/ARRB2; this interaction mediates internalization of TGFBR3 and thus regulates migration, actin cytoskeleton and activation of CDC42. (Microbial infection) Interacts with human cytomegalovirus trimer complex composed of gH, gL, and gO; these interactions may promote HCMV cell entry in specific cell types.

Subcellular location. Cell membrane. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Extensively modified by glycosaminoglycan groups (GAG). Phosphorylated in the cytoplasmic domain by the type II receptor TGFBR2 at THR-840 to mediate recruitment of ARRB2 and subsequent internalization of TGFBR2 and TGFBR3.

Isoforms (2)

UniProt ID	Names	Canonical?
Q03167-1	1	yes
Q03167-2	2

RefSeq proteins (3): NP_001182612, NP_001182613, NP_003234* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001507	ZP_dom	Domain
IPR017977	ZP_dom_CS	Conserved_site
IPR042235	ZP-C_dom	Homologous_superfamily
IPR048290	ZP_chr	Domain
IPR055355	ZP-C	Domain
IPR055356	ZP-N	Domain
IPR058899	TGFBR3/Endoglin-like_N	Domain

Pfam: PF00100, PF23344, PF26060

UniProt features (47 total): strand 11, glycosylation site 7, sequence variant 7, disulfide bond 4, helix 3, topological domain 2, sequence conflict 2, region of interest 2, compositionally biased region 2, signal peptide 1, chain 1, modified residue 1, splice variant 1, transmembrane region 1, mutagenesis site 1, domain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7LBG	ELECTRON MICROSCOPY	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q03167-F1	71.58	0.27

Antibody-complex structures (SAbDab): 1 — 7LBG

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 840

Disulfide bonds (4): 52–197, 639–705, 660–730, 710–723

Glycosylation sites (7): 141, 492, 534, 545, 571, 590, 697

Mutagenesis-validated functional residues (1):

Position	Phenotype
840	partial loss of phosphorylation by tgfbr2.

Function

Pathways and Gene Ontology

Reactome pathways

18 pathways

ID	Pathway
R-HSA-1502540	Signaling by Activin
R-HSA-190370	FGFR1b ligand binding and activation
R-HSA-190373	FGFR1c ligand binding and activation
R-HSA-201451	Signaling by BMP
R-HSA-2173789	TGF-beta receptor signaling activates SMADs
R-HSA-9839383	TGFBR3 PTM regulation
R-HSA-9839389	TGFBR3 regulates TGF-beta signaling
R-HSA-9839394	TGFBR3 expression
R-HSA-9839397	TGFBR3 regulates FGF2 signaling
R-HSA-9839406	TGFBR3 regulates activin signaling
R-HSA-162582	Signal Transduction
R-HSA-170834	Signaling by TGF-beta Receptor Complex
R-HSA-190236	Signaling by FGFR
R-HSA-190242	FGFR1 ligand binding and activation
R-HSA-5654736	Signaling by FGFR1
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases
R-HSA-9006936	Signaling by TGFB family members
R-HSA-9839373	Signaling by TGFBR3

MSigDB gene sets: 598 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_CARDIAC_SEPTUM_DEVELOPMENT, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_VENTRICULAR_SEPTUM_MORPHOGENESIS, GOBP_CORONARY_VASCULATURE_DEVELOPMENT, DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN, GOBP_HEART_TRABECULA_MORPHOGENESIS

GO Biological Process (43): response to hypoxia (GO:0001666), epithelial to mesenchymal transition (GO:0001837), liver development (GO:0001889), heart morphogenesis (GO:0003007), muscular septum morphogenesis (GO:0003150), outflow tract morphogenesis (GO:0003151), ventricular compact myocardium morphogenesis (GO:0003223), immune response (GO:0006955), transforming growth factor beta receptor signaling pathway (GO:0007179), transforming growth factor beta receptor complex assembly (GO:0007181), positive regulation of gene expression (GO:0010628), cell migration (GO:0016477), regulation of transforming growth factor beta receptor signaling pathway (GO:0017015), negative regulation of cell migration (GO:0030336), BMP signaling pathway (GO:0030509), positive regulation of transforming growth factor beta receptor signaling pathway (GO:0030511), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), animal organ regeneration (GO:0031100), response to follicle-stimulating hormone (GO:0032354), response to prostaglandin E (GO:0034695), response to luteinizing hormone (GO:0034699), intracellular signal transduction (GO:0035556), negative regulation of canonical NF-kappaB signal transduction (GO:0043124), negative regulation of epithelial cell proliferation (GO:0050680), ventricular cardiac muscle tissue morphogenesis (GO:0055010), cardiac muscle cell proliferation (GO:0060038), positive regulation of cardiac muscle cell proliferation (GO:0060045), definitive hemopoiesis (GO:0060216), cardiac epithelial to mesenchymal transition (GO:0060317), definitive erythrocyte differentiation (GO:0060318), heart trabecula formation (GO:0060347), positive regulation of SMAD protein signal transduction (GO:0060391), negative regulation of SMAD protein signal transduction (GO:0060392), ventricular septum morphogenesis (GO:0060412), epicardium-derived cardiac fibroblast cell development (GO:0060939), vasculogenesis involved in coronary vascular morphogenesis (GO:0060979), heart trabecula morphogenesis (GO:0061384), secondary palate development (GO:0062009), positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050), negative regulation of extracellular matrix assembly (GO:1901202)

GO Molecular Function (15): transmembrane signaling receptor activity (GO:0004888), transforming growth factor beta receptor activity (GO:0005024), type II transforming growth factor beta receptor binding (GO:0005114), transforming growth factor beta receptor binding (GO:0005160), glycosaminoglycan binding (GO:0005539), heparin binding (GO:0008201), coreceptor activity (GO:0015026), fibroblast growth factor binding (GO:0017134), PDZ domain binding (GO:0030165), BMP binding (GO:0036122), SMAD binding (GO:0046332), activin binding (GO:0048185), transforming growth factor beta binding (GO:0050431), transforming growth factor beta receptor activity, type III (GO:0070123), protein binding (GO:0005515)

GO Cellular Component (12): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), cytosol (GO:0005829), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), basolateral plasma membrane (GO:0016323), inhibin-betaglycan-ActRII complex (GO:0034673), signaling receptor complex (GO:0043235), extracellular exosome (GO:0070062), membrane (GO:0016020), cell periphery (GO:0071944)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Signaling by TGFBR3	5
Signaling by TGFB family members	4
FGFR1 ligand binding and activation	2
Signal Transduction	2
Signaling by TGF-beta Receptor Complex	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by FGFR1	1
Signaling by FGFR	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
transforming growth factor beta receptor signaling pathway	4
transforming growth factor beta receptor superfamily signaling pathway	2
regulation of transforming growth factor beta receptor signaling pathway	2
signaling receptor activity	2
growth factor binding	2
cytokine binding	2
response to stress	1
response to decreased oxygen levels	1
mesenchymal cell differentiation	1
gland development	1
hepaticobiliary system development	1
heart development	1
animal organ morphogenesis	1
ventricular septum morphogenesis	1
muscle tissue morphogenesis	1
heart morphogenesis	1
anatomical structure morphogenesis	1
ventricular cardiac muscle tissue morphogenesis	1
immune system process	1
response to stimulus	1
cellular response to transforming growth factor beta stimulus	1
protein-containing complex assembly	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
cell motility	1
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regulation of cellular response to transforming growth factor beta stimulus	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
cellular response to BMP stimulus	1
positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
positive regulation of cellular response to transforming growth factor beta stimulus	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regeneration	1
animal organ development	1
response to gonadotropin	1
response to prostaglandin	1

Protein interactions and networks

STRING

2302 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TGFBR3	TGFB2	P08112	995
TGFBR3	TGFB1	P01137	992
TGFBR3	TGFB3	P10600	989
TGFBR3	TGFBR1	P36897	976
TGFBR3	TGFBR2	P37173	966
TGFBR3	ACVR2A	P27037	843
TGFBR3	BMP2	P12643	825
TGFBR3	WLS	Q5T9L3	791
TGFBR3	CLEC7A	Q9BXN2	767
TGFBR3	BMP4	P12644	751
TGFBR3	ARRB2	P32121	744
TGFBR3	GDF5	P43026	708
TGFBR3	INHA	P05111	673
TGFBR3	ARRB1	P49407	651
TGFBR3	ACVR2B	Q13705	640

IntAct

44 interactions, top by confidence:

A	B	Type	Score
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
TGFBR3	FGFR4	psi-mi:“MI:0407”(direct interaction)	0.560
PDPK1	AGRN	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
DEFA5	NUDT19	psi-mi:“MI:0914”(association)	0.530
LRRTM4	AP3B1	psi-mi:“MI:0914”(association)	0.530
DEFA1	MANBA	psi-mi:“MI:0914”(association)	0.530
HADHA	AGRN	psi-mi:“MI:0914”(association)	0.530
TAFA4	NRP1	psi-mi:“MI:0914”(association)	0.530
GPR183	NRP1	psi-mi:“MI:0914”(association)	0.530
FGF1	SDC4	psi-mi:“MI:0914”(association)	0.530
TGFBR3	GIPC1	psi-mi:“MI:0915”(physical association)	0.510
TGFB1	TGFBR3	psi-mi:“MI:0407”(direct interaction)	0.440
TGFB3	TGFBR3	psi-mi:“MI:0407”(direct interaction)	0.440
ST8SIA4	FAM234B	psi-mi:“MI:0914”(association)	0.350
DKKL1	VWA8	psi-mi:“MI:0914”(association)	0.350
KLK11	DENND11	psi-mi:“MI:0914”(association)	0.350
SHISA3	ZNF316	psi-mi:“MI:0914”(association)	0.350
PSCA	METTL15	psi-mi:“MI:0914”(association)	0.350
KLRC1	METTL15	psi-mi:“MI:0914”(association)	0.350
ST14	LIPT2	psi-mi:“MI:0914”(association)	0.350
FGF4	AGRN	psi-mi:“MI:0914”(association)	0.350
TMPRSS13	TOR1A	psi-mi:“MI:0914”(association)	0.350
HPN	TOR1A	psi-mi:“MI:0914”(association)	0.350

BioGRID (66): TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS), TGFBR3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0A6YXX9, A0A1Z2R986, B8RJM0, E9Q555, E9Q612, G5E8Q8, O35664, O88393, P09258, P0DP43, P13374, P20746, P22596, P22650, P22651, P26342, P33500, P35054, P48749, P68325, Q03167, Q14CH0, Q16827, Q2TAV2, Q2YDM0, Q56A20, Q5BKX0, Q5R7R7, Q5RBQ2, Q5U228, Q68FB2, Q6NU22, Q6NU51, Q6P995, Q6S6Q5, Q6UC88, Q76B58, Q77NN4, Q7SXB3, Q8K1M8

Diamond homologs: A0A1Z2R986, P17813, P37176, Q03167, Q63961, O88393, P26342, P35054

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CREB5	“up-regulates quantity by expression”	TGFBR3	“transcriptional regulation”
INHA	down-regulates	TGFBR3	binding
TGFB2	up-regulates	TGFBR3	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 58 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PIP3 activates AKT signaling	6	9.5×	5e-04

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cell division	5	31.2×	2e-04
neural tube closure	5	17.3×	1e-03
regulation of cell migration	5	14.6×	2e-03
positive regulation of ERK1 and ERK2 cascade	7	11.0×	7e-04

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

144 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	98
Likely benign	21
Benign	10

Top pathogenic / likely-pathogenic (0)

SpliceAI

4453 predictions. Top by Δscore:

Variant	Effect	Δscore
1:91695667:CTAA:C	donor_loss	1.0000
1:91695668:TAA:T	donor_loss	1.0000
1:91695669:AAC:A	donor_loss	1.0000
1:91695670:A:T	donor_loss	1.0000
1:91695671:C:CT	donor_loss	1.0000
1:91695778:TG:T	acceptor_gain	1.0000
1:91698087:A:AC	donor_gain	1.0000
1:91698088:C:CC	donor_gain	1.0000
1:91708782:CA:C	acceptor_gain	1.0000
1:91708784:C:CC	acceptor_gain	1.0000
1:91712240:AAC:A	donor_loss	1.0000
1:91712241:A:C	donor_loss	1.0000
1:91712540:TACC:T	acceptor_loss	1.0000
1:91712543:C:G	acceptor_loss	1.0000
1:91716390:TTAAA:T	acceptor_gain	1.0000
1:91716395:C:CC	acceptor_gain	1.0000
1:91716564:ATACC:A	donor_loss	1.0000
1:91716566:ACCAC:A	donor_gain	1.0000
1:91716567:CCA:C	donor_gain	1.0000
1:91716567:CCACC:C	donor_gain	1.0000
1:91716704:ACAAT:A	acceptor_gain	1.0000
1:91716705:CAAT:C	acceptor_gain	1.0000
1:91716705:CAATC:C	acceptor_gain	1.0000
1:91716706:AAT:A	acceptor_gain	1.0000
1:91716707:AT:A	acceptor_gain	1.0000
1:91716709:C:CC	acceptor_gain	1.0000
1:91719310:A:AC	donor_gain	1.0000
1:91719311:C:CC	donor_gain	1.0000
1:91719460:CTGGC:C	acceptor_gain	1.0000
1:91719868:C:A	donor_gain	1.0000

AlphaMissense

5612 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:91712494:A:G	C639R	0.999
1:91712346:A:G	F688S	0.998
1:91712492:G:C	C639W	0.998
1:91716240:A:T	V621D	0.998
1:91712296:A:G	C705R	0.997
1:91712493:C:T	C639Y	0.997
1:91727703:A:G	W281R	0.997
1:91727703:A:T	W281R	0.997
1:91712295:C:G	C705S	0.996
1:91712296:A:T	C705S	0.996
1:91712493:C:G	C639S	0.996
1:91712494:A:T	C639S	0.996
1:91695728:G:T	A794D	0.995
1:91712280:C:G	C710S	0.995
1:91712281:A:G	C710R	0.995
1:91712281:A:T	C710S	0.995
1:91712301:A:G	L703P	0.995
1:91712346:A:C	F688C	0.995
1:91712430:C:G	C660S	0.995
1:91712431:A:T	C660S	0.995
1:91729952:C:G	C197S	0.995
1:91729953:A:T	C197S	0.995
1:91734827:A:G	S173P	0.995
1:91758663:A:G	W112R	0.995
1:91758663:A:T	W112R	0.995
1:91695693:A:G	W806R	0.994
1:91695693:A:T	W806R	0.994
1:91695707:A:G	L801P	0.994
1:91695737:G:T	A791E	0.994
1:91712340:A:G	F690S	0.994

dbSNP variants (sampled 300 via entrez): RS1000017637 (1:91697457 G>A), RS1000043196 (1:91894899 T>C), RS1000058247 (1:91755884 A>G), RS1000069414 (1:91843409 C>T), RS1000095984 (1:91850580 AG>A), RS1000100193 (1:91900799 C>T), RS1000103077 (1:91764007 T>C), RS1000109208 (1:91883672 T>C), RS1000131003 (1:91719216 C>A,T), RS1000154770 (1:91806201 C>T), RS1000158791 (1:91894587 G>A,C,T), RS1000168936 (1:91804781 C>T), RS1000175986 (1:91762494 G>A), RS1000194335 (1:91785783 T>C), RS1000217231 (1:91797218 G>A,T)

Disease associations

OMIM: gene MIM:600742 | disease phenotypes: MIM:607086

GenCC curated gene-disease

Mondo (4): infertility disorder (MONDO:0005047), prostate cancer (MONDO:0008315), familial thoracic aortic aneurysm and aortic dissection (MONDO:0019625), connective tissue disorder (MONDO:0003900)

Orphanet (2): Familial prostate cancer (Orphanet:1331), Familial thoracic aortic aneurysm and aortic dissection (Orphanet:91387)

HPO phenotypes

15 total (15 of 15 shown, HPO-id order):

HPO	Term
HP:0000822	Hypertension
HP:0001123	Visual field defect
HP:0001250	Seizure
HP:0001269	Hemiparesis
HP:0002138	Subarachnoid hemorrhage
HP:0002170	Intracranial hemorrhage
HP:0002326	Transient ischemic attack
HP:0002363	Abnormal brainstem morphology
HP:0002616	Aortic root aneurysm
HP:0002621	Atherosclerosis
HP:0002647	Aortic dissection
HP:0007029	Cerebral berry aneurysm
HP:0012246	Oculomotor nerve palsy
HP:0012518	Abnormal circle of Willis morphology
HP:0040197	Encephalomalacia

GWAS associations

38 associations (top):

Study	Trait	p-value
GCST000347_2	Bone mineral density	1.000000e-06
GCST000699_3	Optic disc parameters	3.000000e-28
GCST000970_3	Optic disc area	8.000000e-17
GCST001759_3	Type 2 diabetes	4.000000e-06
GCST002626_1	Vertical cup-disc ratio	1.000000e-15
GCST002765_1	Optic disc area	8.000000e-56
GCST002765_6	Optic disc area	4.000000e-38
GCST004010_1	QT interval (tricyclic/tetracyclic antidepressant use interaction)	3.000000e-08
GCST004047_1	Optic nerve measurement (cup-to-disc ratio)	1.000000e-07
GCST004075_26	Vertical cup-disc ratio	3.000000e-20
GCST004075_27	Vertical cup-disc ratio	2.000000e-23
GCST004076_16	Optic disc area	6.000000e-81
GCST004076_2	Optic disc area	2.000000e-60
GCST004162_5	Carotid plaque burden	7.000000e-06
GCST004185_5	Lung function (FEV1/FVC)	6.000000e-20
GCST004185_6	Lung function (FEV1/FVC)	1.000000e-09
GCST004763_1	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	9.000000e-07
GCST004899_6	Gestational age at birth (maternal effect)	9.000000e-07
GCST006626_40	Pulse pressure	2.000000e-10
GCST006979_992	Heel bone mineral density	4.000000e-13
GCST007429_94	Lung function (FVC)	1.000000e-10
GCST007430_69	Peak expiratory flow	2.000000e-08
GCST007430_70	Peak expiratory flow	3.000000e-09
GCST007431_109	Lung function (FEV1/FVC)	5.000000e-09
GCST007431_67	Lung function (FEV1/FVC)	2.000000e-47
GCST007431_68	Lung function (FEV1/FVC)	2.000000e-21
GCST008391_1	Glaucoma (primary open-angle)	2.000000e-08
GCST008482_1	Lung function (FVC)	8.000000e-07
GCST009411_10	Optic disc area	4.000000e-64
GCST009412_8	Vertical cup-disc ratio	1.000000e-18

EFO canonical traits (14, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval
EFO:0007916	response to tricyclic antidepressant
EFO:0006939	cup-to-disc ratio measurement
EFO:0006501	carotid plaque build
EFO:0004713	FEV/FVC ratio
EFO:0007805	HDL cholesterol change measurement
EFO:0005112	gestational age
EFO:0005939	parental genotype effect measurement
EFO:0005763	pulse pressure measurement
EFO:0009270	heel bone mineral density
EFO:0004312	vital capacity
EFO:0009718	peak expiratory flow
EFO:0004469	HOMA-B
EFO:0004980	appendicular lean mass

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D003240	Connective Tissue Diseases	C17.300
D007246	Infertility	C12.100.750
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs12082710	Efficacy	3	antidepressants	Depression

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs12082710	TGFBR3	3	2.50	1	antidepressants

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Type III receptor serine/threonine kinases

CTD chemical–gene interactions

73 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases expression, affects methylation	3
Tetrachlorodibenzodioxin	affects expression, decreases expression	3
Valproic Acid	affects expression, decreases expression, increases expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	3
Cyclosporine	decreases expression	3
Particulate Matter	decreases expression, increases abundance, affects cotreatment	3
bisphenol A	affects expression, affects methylation	2
methylselenic acid	increases expression	2
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Air Pollutants	decreases expression, increases abundance	2
Benzene	increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	affects cotreatment, decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, increases methylation	1
dicrotophos	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	decreases expression	1
trichostatin A	increases expression	1
styrene oxide	affects expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
hydroquinone	decreases expression	1
nivalenol	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B9T7	Abcam A-549 TGFBR3 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01388907	PHASE4	COMPLETED	Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
NCT01430650	PHASE4	COMPLETED	Endometrial Priming for Embryo Transfer
NCT02607319	PHASE4	COMPLETED	Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
NCT03169166	PHASE4	COMPLETED	The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
NCT03177122	PHASE4	UNKNOWN	Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03477929	PHASE4	UNKNOWN	Cetrorelix and Ganirelix Flexible Protocol for (IVF)
NCT03619707	PHASE4	COMPLETED	Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
NCT03846544	PHASE4	COMPLETED	Double Pick up in Poor Prognosis Women
NCT05725512	PHASE4	RECRUITING	Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
NCT06195163	PHASE4	NOT_YET_RECRUITING	TRAP Study: Testosterone for Androgen Receptor Polymorphism
NCT06763926	PHASE4	NOT_YET_RECRUITING	Intranasal Nafarelin For Triggering Oocyte Maturation
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration